Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer  by Chiappori, Alberto et al.
ORIGINAL ARTICLE
Phase II, Double-Blinded, Randomized Study of Enzastaurin
Plus Pemetrexed as Second-Line Therapy in Patients with
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Keunchil Park, MD,** Asavari Wagle, MS,†† Astra M. Liepa, PhD,†† Yan Daniel Zhao, PhD,††
Nadia Chouaki, PhD,‡‡ Neill Iscoe, MD,§§ and Joachim von Pawel, MD
Introduction: We examined the efficacy of enzastaurin plus pem-
etrexed as second-line therapy in patients with advanced (stage
IIIA/B or IV) non-small cell lung cancer in a double-blinded,
randomized, phase II study.
Methods: Patients received pemetrexed 500 mg/m2 intravenously
on day 1 of 21-day cycles (day 8 in cycle 1) plus oral enzastaurin
(250 mg two times per day; combination arm) or placebo (pem-
etrexed arm). Both arms received supplementation with vitamin B12,
folic acid, and dexamethasone. An interim analysis was conducted
to determine whether efficacy would warrant a phase III study.
Results: The interim analysis showed no evidence of improved
progression-free survival with enzastaurin. At final analysis (N 
160, 80 in each arm), baseline characteristics were well balanced.
There was no significant difference in progression-free survival (3.0
months, p  0.544) or overall survival (9.6 months in combination
arm and 7.4 months in pemetrexed arm, p  0.171). Drug-related
serious adverse events included cerebrovascular accident, palpita-
tions, and renal failure (n  1, each) in combination arm and
neutropenic sepsis, thrombocytopenia, and panniculitis (n 1, each)
in pemetrexed arm. Nonhematologic drug-related grade 3/4 toxici-
ties were similar in both arms. Grade 3/4 hematologic toxicities were
higher with the combination, specifically leukopenia (6.3% versus
0%), neutropenia (15.2% versus 5.0%), and thrombocytopenia
(8.9% versus 1.3%). Of the 26 deaths reported on-study or within 30
days of discontinuation (10 in combination arm and 16 in pem-
etrexed arm), none were drug related.
Conclusion: The combination regimen of enzastaurin and pem-
etrexed is well tolerated but does not improve efficacy over pem-
etrexed and placebo as second-line treatment of unselected patients
with advanced non-small cell lung cancer.
Key Words: Phase II, Non-small cell lung cancer, Enzastaurin,
Pemetrexed.
(J Thorac Oncol. 2010;5: 369–375)
Lung cancer is the most common cancer in the world, andapproximately 85% of all lung cancers are non-small cell
lung cancer (NSCLC).1 Despite advances in treatment, mor-
bidity and overall survival (OS) remain poor. This under-
scores the need for innovative treatment options that target
the underlying molecular mechanisms of the disease.2
Enzastaurin, an oral serine/threonine kinase inhibitor,
targets both the protein kinase C (PKC) and AKT pathways
and induces tumor cell apoptosis, reduces proliferation, and
suppresses angiogenesis.3 PKC and AKT have been impli-
cated in tumorigenesis, treatment efficacy, and outcome in
NSCLC.4–8 The antitumor and antiangiogenic activity of
enzastaurin was demonstrated in preclinical lung cancer mod-
els9–11 and was confirmed using a standardized clonogenic
assay in patient-derived tumor explants.12 Target inhibition
was demonstrated in a pharmacodynamic study in patients
with breast cancer, wherein enzastaurin treatment led to a
significant decrease in cytoplasmic PKCb2, phospho-GSK3,
and phospho-S6kinase in tumor tissue.13 In clinical studies,
enzastaurin showed promising activity in multiple solid tu-
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mors and hematologic cancers and is well tolerated up to
700 mg.14,15 In a phase II study of single-agent enzastaurin as
second- or third-line therapy in patients with metastatic
NSCLC, enzastaurin was well tolerated. Additionally, 13% of
the patients had disease stabilization for 6 months, and 11%
of patients had prolonged stabilization (up to 20 months).16
Given its mechanism of action and tolerability, enza-
staurin was considered to be of interest in combination
regimens to potentially enhance clinical efficacy, similar to
other targeted therapies.17–20 When administered in combina-
tion with other agents, enzastaurin did not lead to an in-
creased toxicity profile.21,22 In preclinical studies, a synergis-
tic antitumor activity was observed when enzastaurin was
combined with pemetrexed,23 a multitargeted antifolate with
activity in NSCLC.24,25 In a phase Ib study, the combination
of enzastaurin plus pemetrexed was well tolerated and
showed preliminary evidence of anticancer activity.26 Addi-
tionally, pharmacokinetic parameters of the two drugs were
not altered when given in combination.
We initiated a double-blinded, placebo-controlled, ran-
domized phase II study to determine whether the combination
of enzastaurin and pemetrexed would improve progression-
free survival (PFS) in patients receiving second-line therapy
for advanced NSCLC. Secondary objectives included OS,
tumor response, time to worsening of symptoms (TWS), and
safety.
PATIENTS AND METHODS
Eligibility Criteria
Patients aged 18 years and older with an Eastern Coop-
erative Oncology Group performance status (ECOG PS) of 0 to
2, adequate organ function, and a histologic or cytologic diag-
nosis of locally advanced or metastatic NSCLC (stage IIIA, IIIB,
or IV) not amenable to curative therapy were eligible.
Patients must have had progressive disease after one
prior systemic chemotherapy regimen for advanced disease,
discontinued all previous systemic therapies for cancer for at
least 2 weeks before enrollment, and had at least one mea-
surable lesion as defined by RECIST.27
Patients were excluded from the study if they received
previous treatment with enzastaurin or pemetrexed or had a
serious chronic illness. Other exclusion criteria included
presence of clinically significant third-space fluid collections;
central nervous system metastases (unless treated and if
patient was off corticosteroids for 4 weeks before enroll-
ment); ECG abnormalities, a myocardial infarction within 6
months, angina, or other clinically significant cardiac abnor-
malities; second primary malignancy that was clinically de-
tectable; concurrent administration of any other antitumor
therapy; inability to interrupt aspirin or other nonsteroidal
antiinflammatory agents; and inability to discontinue use of
carbamazepine, phenobarbital, and phenytoin.
The protocol was approved by each participating insti-
tution’s ethics review board. Written informed consent was
obtained from each patient before study enrollment. The
study was conducted in accordance with the ethical principles
of the Declaration of Helsinki and good clinical practices and
applicable laws and regulations.
Study Design and Treatment Plan
Patients were assigned to receive either enzastaurin plus
pemetrexed (combination arm) or placebo plus pemetrexed
(pemetrexed arm). Because emerging information suggested that
higher plasma levels of enzastaurin are achieved with two times
per day dosing28 and because no additional toxicity was ob-
served with two times per day dosing compared with once per
day in a previous study of enzastaurin in combination with
pemetrexed,26 the decision was made to treat all patients in the
combination arm with two times per day dosing of enzastaurin.
Patients received 250 mg enzastaurin two times per day, with a
loading dose of 1125 mg (375 mg three times per day) on day 1
of a 28-day cycle 1, plus intravenous 500 mg/m2 pemetrexed on
day 8 in cycle 1 and on day 1 of subsequent 21-day cycles.
Patients in the pemetrexed arm received placebo plus intrave-
nous 500 mg/m2 pemetrexed. All patients received supplemental
dexamethasone, folic acid, and vitamin B12 as per the pem-
etrexed label. Study treatment continued until progressive dis-
ease or unacceptable toxicity occurred.
Dose Modifications
Pemetrexed was reduced by 25% for platelets 50 
109/liter and an absolute neutrophil count (ANC) 0.5 
109/liter; platelets 50  109/liter; an ANC 1.0  109/liter
with fever; or grade 3/4 toxicity (including hematologic toxicity,
diarrhea, and grade 4 transaminase elevations). Pemetrexed was
reduced by 50% for platelets 50  109/liter with bleeding or
grade 3/4 mucositis. Any patient who required a dose reduction
of pemetrexed continued to receive the reduced dose for the
remainder of the study. Pemetrexed was discontinued if any
grade 3/4 toxicity occurred after two dose reductions or if the
toxicity did not resolve to baseline after 42 days.
Enzastaurin or placebo was omitted for an ANC
0.5  109/liter for longer than 7 days or an ANC 1.0 
109/liter with fever; platelets 25  109/liter; or clinically
relevant grade 3 or 4 nonhematologic toxicity. After the event
resolved to grade 1 or baseline, treatment was restarted at
50% of the dose and was resumed at the full dose if the
toxicity did not recur after 21 days. If the toxicity did not
resolve to grade 1 or baseline after 21 days, treatment was
discontinued.
Treatment Assessments
Tumor measurements, medical and physical examina-
tions, ECOG PS evaluation, and serum chemistry were com-
pleted at baseline and before each cycle. Hematology was
performed at baseline and every week starting on day 8 of
cycle 1. Tumors were measured using either computed to-
mography or magnetic resonance imaging (same method used
throughout the study). Chest x-ray was acceptable if the lesion(s)
was clearly defined and surrounded by aerated lung. Response
was confirmed no less than 4 weeks from the first evidence of
response using the RECIST guidelines. Thereafter, a responding
patient was followed up every 6 weeks (2 weeks).
PFS was measured from the date of randomization to
the first date of documented objective progression of disease
or of death from any cause. OS was measured from the date
of randomization to the date of death from any cause. Disease
control comprised stable disease plus partial response plus
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complete response. Patient-reported symptoms and health-
related quality of life (HRQL) were assessed using the Lung
Cancer Symptom Scale (LCSS) at baseline, the end of each
cycle, at discontinuation, and 30 days after discontinuation.29
For each LCSS item, TWS was measured from the date of
randomization to the date of the first increase of 15 mm (on
the 100-mm visual analogue scale) as described previously.30
Safety was assessed before each cycle using the Common
Terminology Criteria for Adverse Events (v3.0).
Statistical Methods
Assuming a 25% censor rate, 160 patients were to be
enrolled in this study to have 120 events for the final analysis,
which would provide 80% power to detect an increase in
median PFS from 3.0 months to 4.1 months (hazard ratio
[HR]  0.735). An interim analysis was planned after a total
of 60 PFS events to determine whether there was sufficient
early evidence of efficacy with treatment of enzastaurin plus
pemetrexed to warrant the initiation of a phase III study or to
stop the study for futility. The study was to be terminated for
lack of efficacy if the HR was 1 at the interim analysis.
Survival analyses were performed on the intent-to-treat
population. Response rate and safety analyses were con-
ducted on patients who had at least one dose of the study
drug. TWS analyses were conducted on patients who pro-
vided LCSS data at baseline and postbaseline. PFS was
analyzed using the stratified log-rank test with ECOG PS and
time since last chemotherapy as the stratification factors.
Additional Cox model analyses were conducted on PFS,
considering additional potential prognostic factors including
prior response to first-line chemotherapy, use of prior anti-
angiogenic treatment, histology, and gender as covariates in
the model. The Kaplan-Meier method was used to estimate
parameters specific to each treatment group for all time-to-
event variables. Disease control and tumor response rates in
the two arms were compared using Fisher’s exact test.
RESULTS
Conduct of Study
The interim analysis was initiated after 60 PFS events
(117 patients). The study was stopped after the results of the
interim analysis indicated that treatment with enzastaurin plus
pemetrexed would not result in the expected improvement in
PFS as the observed PFS HR was 1.24. All patients were
discontinued from study therapy. However, enrollment was
rapid and continued while the interim analysis was being per-
formed. Thus, by the time the interim analysis was completed,
the trial was fully enrolled (160 patients), and 72 PFS events had
occurred. The results of the final analysis presented here are
based on outcomes data that were finalized in December 2008.
Patient Characteristics
At 23 sites in six countries, 160 patients (80 in each
treatment arm) were entered into this study and randomized
from September 2007 to October 2008. Baseline characteris-
tics (Table 1) were well balanced (median age of 61.4 years,
32.5% women, 89.0% whites, 92.5% ECOG PS 0 or 1, and
85.9% ever smokers). In the combination and pemetrexed arms,
66.3% and 77.5% of patients had nonsquamous histology and
33.8% and 22.5% had squamous histology. LCSS scores at
baseline were not statistically different between arms.
Treatment Administration
Seventy-nine patients in the combination arm and eight
patients in the pemetrexed arm received at least one dose of
study drug. A total of 24 (30.4%) patients in the combination
arm and 27 (33.8%) patients in the pemetrexed arm received6
cycles of treatment. Seven patients in the combination arm and
five patients in the pemetrexed arm discontinued due to drug-
related adverse events, including serious adverse events of ce-
rebrovascular accident, palpitations, and renal failure in the
combination arm (n  1, each) and neutropenic sepsis, thrombo-
cytopenia, and panniculitis in the pemetrexed arm (n 1, each).
Efficacy and Patient-Reported Outcomes
There was no significant difference in PFS (Figure 1A)
between arms (median, 3.0 months per arm; p  0.544;
HR  1.13; 95% confidence interval [CI]: 0.77–1.65). The
median OS (Figure 1B) was 9.6 months (95% CI: 8.18–NA)
in the combination arm (66.3% censored) and 7.4 months
(95% CI: 6.41–NA) in the pemetrexed arm (56.3% censored;
p  0.171; HR  0.70; 95% CI: 0.42–1.17). The tumor
response rates (3.9% and 2.6%) and disease control rates
(49.4% and 48.7%) were not significantly different in the
TABLE 1. Baseline Patient Demographics and Disease
Characteristics
N  160
Enzastaurin 
Pemetrexed
(N  80)
Placebo 
Pemetrexed
(N  80)
Age (yr)
Median (range) 62.1 (35–81) 60.7 (43–87)
Gender (%)
Female 32.5 32.5
Male 67.5 67.5
Origin (%)
White 86.3 91.3
African 3.8 1.3
East Asian 10.0 7.5
Smoking status (%)
Never smoker 14.1 14.1
Ever smoker 85.9 85.9
ECOG performance status (%)
0 or 1 92.5 92.5
2 7.5 7.5
Disease stage (%)
IIIA 3.8 3.8
IIIB 20.0 28.8
IV 76.3 67.5
Response to prior therapy (%)
CR 5.0 1.3
PR 41.3 36.3
SD 35.0 41.3
ECOG, Eastern Cooperative Oncology Group; CR, complete response; PR, partial
response; SD, stable disease.
Journal of Thoracic Oncology • Volume 5, Number 3, March 2010 Enzastaurin Plus Pemetrexed as Second-Line Therapy
Copyright © 2010 by the International Association for the Study of Lung Cancer 371
evaluable populations (N  77 and 78) in the combination
and pemetrexed arms, respectively (Table 2).
In the 64 patients from each arm included in the TWS
analyses, Global HRQL was the only LCSS item for which
there was a statistical difference between arms, with a longer
time to worsening for the pemetrexed arm (median 8.1 versus
3.1 months; p  0.01). In the pemetrexed arm, median TWS
for anorexia, fatigue, dyspnea, pain, symptom distress, and
interference with activity level ranged from 2.4 to 3.8
months; median TWS was not estimable for cough or hemop-
tysis due to censoring. The median TWS in the combination
arm for these symptoms was not significantly different
(range: 1.9–3.8 months).
A significant interaction between treatment arm and
histology was observed for OS (p  0.031; Table 3). Al-
though the median OS for patients with nonsquamous histol-
ogy was the same in both arms (8.2 months; Figure 2A), it
was significantly different in patients with squamous cell
histology (Figure 2B). The median OS in the combination
arm was not reached due to an insufficient number of events
(81.5% censored) and was 6.4 months in the pemetrexed arm
(p  0.016; HR  0.25; 95% CI: 0.08–0.77; 50.0% cen-
sored). However, as shown in Table 3, there was no signifi-
cant difference by histology in median PFS (p  0.331).
Baseline characteristics of patients with squamous histology
were not different between arms.
Safety
Nonhematologic grade 3/4 toxicities possibly related to
study drug were similar in both arms (Table 4), with fatigue
being the most common (11.4% in the combination arm,
7.5% in the pemetrexed arm). The incidence of grade 3/4
hematologic toxicities (Table 4) possibly related to study
drug was higher with the combination treatment, specifically,
leukopenia (6.3% versus 0%, p 0.028), neutropenia (15.2%
versus 5.0%, p 0.038), and thrombocytopenia (8.9% versus
1.3%, p  0.034). However, there was no significant differ-
ence in febrile neutropenia (3.8% in the combination arm;
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FIGURE 1. A, Progression-free survival (PFS) in intent-to-
treat population. There was no significant difference in PFS
between arms. B, Overall survival (OS) in intent-to-treat pop-
ulation. There was no significant difference in OS between
arms.
TABLE 2. Tumor Response Rate and Disease Control Rate
Best Response
No. (%) of Patients, 95% CI
Enzastaurin 
Pemetrexed
(N  77a)
Placebo 
Pemetrexed
(N  78a)
SD 35 (45.5), 34–57 36 (46.2), 35–58
PR 3 (3.9), 1–11 2 (2.6), 0–9
CR 0 (0.0), 0.95–1.00 0 (0.0), 0.95–1.00
PD 28 (36.4), 26–48 25 (32.1), 22–44
Response rate (CR  PR) 3 (3.9), 1–11 2 (2.6), 0–9
Disease control rate
(CR  PR  SD)
38 (49.4), 38–61 38 (48.7), 37–60
a Patients were excluded from analysis if they did not have cytologic or histologic
diagnosis of NSCLC, presence of measurable disease as defined in RECIST, or if they
were taking concurrent systemic chemotherapy.
PD, progressive disease; SD, stable disease; PR, partial response; CR, complete
response.
TABLE 3. Survival by Histology
Enzastaurin 
Pemetrexed
(N  80)
Placebo 
Pemetrexed
(N  80)
HR p
Interaction
pn
Median
(mo) n
Median
(mo)
OS
Nonsquamous 53 8.2 62 8.2 0.99 0.964 —
Squamous 27 NA 18 6.4 0.25 0.016a 0.031a
PFS
Nonsquamous 53 3.0 62 3.0 1.18 0.458 —
Squamous 27 3.0 18 2.3 0.76 0.433 0.331
a p values are significant.
HR, hazard ratio; OS, overall survival; PFS, progression-free survival; NA, not
available.
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2.5% in the pemetrexed arm), toxicity-related hospitaliza-
tions, transfusions, or use of growth factors and erythropoi-
esis-stimulating agents. A total of 26 patients died either
during the study or within 30 days after discontinuation
(combination arm: 10; pemetrexed arm: 16); however, none
of the deaths were drug related (Table 5).
Postdiscontinuation Therapy
In the 47 (58.8%) patients in the combination arm and
the 43 (53.8%) patients in the pemetrexed arm who received
postdiscontinuation therapy (PDT), erlotinib was the most
common (32.5% per arm) followed by docetaxel (15.0% and
7.5%), pemetrexed (8.8% and 13.8%), and vinorelbine
(10.0% and 1.3%). The percentage of 43 patients with squa-
mous cell NSCLC who had PDT was higher in the combi-
nation arm than the pemetrexed arm (59.3% versus 33.3%). In
these patients, the most common PDTs received were erlotinib
(25.9% and 27.8%), docetaxel (18.5% and 11.1%), and vinorel-
bine (14.8% and 5.6%). None of the patients in the pemetrexed
arm received pemetrexed after discontinuation from the study,
compared with two patients in the combination arm.
DISCUSSION
This study of second-line therapy with the combination
of enzastaurin and pemetrexed in patients with NSCLC was
undertaken based on a phase I study of this combination in
solid tumors that demonstrated tolerability.26 Moreover, in a
phase II study, single-agent enzastaurin had a 6-month PFS
rate of 13% as second- or third-line treatment in patients with
Time (months)
0 3 6 9 12 15
S
ur
vi
va
l P
ro
ba
bi
lit
y
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pemetrexed 
0
0
Patients at Risk
7
8
1
1
53
62
23
28
Combination
Pemetrexed
41
50
Median Survival
P = 0.964, HR (95% CI), 0.99 (0.56, 1.74)
8.2 months
8.2 months
Combination  
Time (months)
0 3 6 9 12
S
ur
vi
va
l P
ro
ba
bi
lit
y
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Pemetrexed 
Combination  
15
6
8
1
0
0
Patients at Risk
27
18
Combination
Pemetrexed
23
14
Median Survival
P = 0.016, HR (95% CI), 0.25 (0.08, 0.77)
undetermined
6.4 months
A
B
FIGURE 2. A, Overall survival (OS) in nonsquamous popu-
lation. The median OS for patients with nonsquamous histol-
ogy was the same in both arms. B, Overall survival in squa-
mous population. The median OS was significantly different
in patients with squamous cell histology.
TABLE 4. Grade 3/4 CTC Toxicities Possibly Related to
Study Drug
Toxicitya
Number (%) of Patients
Enzastaurin 
Pemetrexed
(N  79)
Placebo 
Pemetrexed
(N  80)
pGrade 3 Grade 4 Grade 3 Grade 4
Hematologic
Anemia 4 (5.1) 0 (0.0) 4 (5.0) 0 (0.0) 0.999
Leukopenia 3 (3.8) 2 (2.5) 0 (0.0) 0 (0.0) 0.028b
Lymphopenia 2 (2.5) 1 (1.3) 0 (0.0) 0 (0.0) 0.120
Neutropenia 7 (8.9) 5 (6.3) 3 (3.8) 1 (1.3) 0.038b
Thrombocytopenia 4 (5.1) 3 (3.8) 0 (0.0) 1 (1.3) 0.034b
Nonhematologic
Anorexia 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0.497
Fatigue 9 (11.4) 0 (0.0) 5 (6.3) 1 (1.3) 0.430
Febrile
neutropenia
2 (2.5) 1 (1.3) 2 (2.5) 0 (0.0) 0.681
Nausea 2 (2.5) 0 (0.0) 1 (1.3) 0 (0.0) 0.620
Rash/desquamation 0 (0.0) 0 (0.0) 2 (2.5) 0 (0.0) 0.497
Vomiting 2 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0.245
a Toxicities listed in at least 5% of treated patients (all toxicities) on either treatment arm.
b p values are significant.
CTC, Common Toxicity Criteria (Version 3.0).
TABLE 5. Reasons for Discontinuation
Enzastaurin 
Pemetrexed
(N  79)
Placebo 
Pemetrexed
(N  80)
Adverse events 11 (13.9) 8 (10.0)
Drug-related nonserious eventsa 4 (5.1) 2 (2.5)
Drug-related serious events 3 (3.8) 3 (3.8)
Progressive disease 47 (59.5) 40 (50.0)
Deaths 3 (3.8) 6 (7.5)
Deaths due to adverse event 1 (1.3) 3 (3.8)
Deaths due to study disease 2 (2.5) 3 (3.8)
Otherb 18 (22.8) 26 (32.5)
a Asthenia, fatigue, confusion, and transient ischemic attack in the combination arm
and asthenia and fatigue in the pemetrexed arm.
b Includes investigator, sponsor, and patient decision.
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advanced NSCLC.16 There is limited clinical evidence of
synergism with dual-agent cytotoxic regimens combined with
targeted agents as first-line therapy in NSCLC.31–33 The
combination of pemetrexed with bevacizumab has shown
encouraging activity.34,35 Given prior preclinical evidence of
synergy between enzastaurin and cytotoxic agents and its
mechanism of action as a proapoptotic and antiangiogenesis
agent, we reasoned that enzastaurin plus pemetrexed might
have superior efficacy compared with single-agent pem-
etrexed as second-line treatment of advanced NSCLC.
To obtain the most accurate assessment of the benefit of
adding enzastaurin to pemetrexed, we decided on a random-
ized phase II trial design with an interim futility analysis.
Traditionally, phase II trials have been conducted by setting
a predetermined efficacy end point based on historical data.
Although initially more time consuming, the inclusion of a
control arm permits a direct estimation of HRs for the
time-to-event variables, thus reducing the possibility of bias
arising from either patient selection or subjective assess-
ments.36,37 Additionally, interim analyses can lead to optimal
study duration and allocation of patient and clinical trial
resources in many disease settings.38
The efficacy, toxicity, and HRQL results observed in
the control arm of pemetrexed plus placebo were consistent
with those of previous findings in other pemetrexed stud-
ies.24,25,30 The addition of enzastaurin to pemetrexed did not
result in excessive toxicity in the experimental treatment arm.
Surprisingly, we did not observe a benefit by adding enza-
staurin to pemetrexed in any of the outcome parameters
measured, despite the preclinical and mechanistic data of
both agents.23 We cannot exclude the possibility of lack of
target inhibition by enzastaurin because pharmacodynamic
tumor assessments were not included in our study. However,
this seems to be an unlikely explanation given the demon-
stration of target inhibition in breast cancer tissue specimens
with the same dose of enzastaurin.13 Alternate explanations
may be that a reduction in cell proliferation triggered by
enzastaurin may render cells less susceptible to cytotoxicity
by pemetrexed or that tumor cell populations in vivo are
likely to display a much wider spectrum of phenotypic
diversity than cells in an artificial in vitro environment. A
lack of enhanced clinical benefit with enzastaurin plus pem-
etrexed has also been observed in other phase II studies.39,40
A significant and consistent treatment advantage for
pemetrexed in patients with nonsquamous histology has been
observed across three studies.24,41,42 The PFS and OS results
with pemetrexed observed in our study for both squamous
and nonsquamous histology were similar to those reported in
previous second-line trials. Interestingly, we observed that
patients with squamous histology had significantly better OS
with the addition of enzastaurin to pemetrexed compared with
pemetrexed and placebo. However, there was no difference in
PFS or tumor response between the histologic groups. More
patients with squamous histology had postdiscontinuation
systemic therapy in the combination group, but there were no
significant differences in the most common therapies admin-
istered. Because the number of patients with squamous his-
tology was small and the analysis was retrospective, further
evaluation of this combination in patients with squamous cell
carcinoma is required to corroborate the results. Additionally,
translational research of molecular markers potentially predic-
tive of enzastaurin activity will hopefully provide guidance for
future patient selection. We plan to assess biomarkers in speci-
mens available from this study using immunohistochemical
techniques to assess target inhibition and interactions between
patient outcomes and biomarkers. In particular, we are interested
in phosphorylation modifications of the enzastaurin target
PKC2 and the downstream kinases GSK3 and S6Kinase,13 as
well as plasma vascular endothelial growth factor levels, which
were prognostic of poor PFS in the phase II study of single-agent
enzastaurin in NSCLC.16
In conclusion, the combination of enzastaurin plus
pemetrexed was well tolerated but did not increase either PFS
or OS when administered as second-line therapy to patients
with advanced NSCLC.
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